Myelofibrosis Treatment Algorithm Discussion: Dr. Nico Gagelmann

Welcome to the Oncology Brothers podcast! In this episode, we had the opportunity to dive deep into the treatment algorithm for myelofibrosis with Dr. Nico Gagelmann of Dana-Farber Cancer Institute.

Join us as we explored:

The critical distinction between primary and secondary myelofibrosis and its implications for treatment

The essential workup needed before initiating therapy, including bone marrow biopsy and mutation analysis

Anemia management strategies, including the use of erythropoiesis-stimulating agents and the innovative drug luspatercept

The role of JAK inhibitors in treatment, including ruxolitinib, momelotinib, pacritinib, and fedratinib, and how to choose among them based on patient needs

The importance of spleen reduction and its correlation with patient outcomes and survival

Insights into the side effect profiles of various treatments and the future of myelofibrosis management

Whether you're a healthcare professional or someone interested in oncology, this episode provides valuable information on navigating the complexities of myelofibrosis treatment.

Listen us on:Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o

Follow us on social media:

•⁠  ⁠X/Twitter: https://x.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/